Skip to main content

Table 3 Pattern of antidiabetic drug treatment in 2006 and 2012

From: Management of type 2 diabetes and its prescription drug cost before and during the economic crisis in Greece: an observational study

  2006 2012 P*
Lifestyle intervention only 38 (4.1) 11 (1.1) 0.001
OAD only 597 (63.6) 573 (56.5) 0.7
 OAD Monotherapy** 165 (27.6) 182 (31.8) 0.4
 Combination (2 drugs)** 307 (51.5) 245 (42.7)
 Combination (3 drugs)** 125 (20.9) 146 (25.5)
Metformin 627 (66.8) 816 (80.4) < 0.001
Sulphonylurea 416 (44.3) 270 (26.6) < 0.001
TZD 159 (17.0) 50 (4.9) < 0.001
Glinide 118 (12.5) 27 (2.7) < 0.001
Acarbose 73 (7.8) 22 (2.2) < 0.001
DPP-IV inhibitor 0 350 (34.5)  
GLP-1 agonist 0 39 (3.8)  
Insulin 303 (32.3) 432 (42.6) 0.09
 1 injection# 91 (30.0) 126 (29.2) 0.001
 2 injections# 118 (38.9) 83 (19.3)
 ≥ 3 Injections# 94 (31.1) 222 (51.5)
 Insulin analog# 151 (49.8) 315 (72.9) <0.001
Units per Kg of body weight 0.5 (0.3) 0.5 (0.3) 0.87
  1. Data are shown as n (%).
  2. *Statistical significance was assessed after adjustment for age and duration of diabetes.
  3. **Percentage refers to those treated with OAD only.
  4. #Percentage refers to those treated with insulin.
  5. OAD: Oral antidiabetic drugs, TZD: thiazolidinediones, GLP-1: glucagon-like peptide-1, DPP-IV: dipeptidyl peptidase-IV.